Japanese drugmaker Takeda Pharmaceutical (TYO: 4502) has announced that it will create a new subsidiary to take over a range of business operations.
The new company will be a joint venture with pharmaceutical services firm PRA Health Sciences. Takeda and PRA previously announced the expansion of their partnership to Japan on February 15, 2017.
The new company, which will be called Takeda-PRA Development Center KK, is scheduled to be effective as of June 1, 2017. Half of the issued shares in the new company will be owned by PRA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze